In the last trading session, 3.95 million ProKidney Corp (NASDAQ:PROK) shares changed hands as the company’s beta touched 1.61. With the company’s per share price at $3.22 changed hands at $0.07 or 2.22% during last session, the market valuation stood at $942.52M. PROK’s last price was a discount, traded about -121.43% off its 52-week high of $7.13. The share price had its 52-week low at $0.46, which suggests the last value was 85.71% up since then. When we look at ProKidney Corp’s average trading volume, we note the 10-day average is 73.05 million shares, with the 3-month average coming to 12.68 million.
Analysts gave the ProKidney Corp (PROK) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.29. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended PROK as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. ProKidney Corp’s EPS for the current quarter is expected to be -0.15.
ProKidney Corp (NASDAQ:PROK) trade information
Instantly PROK was in green as seen at the end of in last trading. With action -12.74%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 40.00%, with the 5-day performance at -12.74% in the red. However, in the 30-day time frame, ProKidney Corp (NASDAQ:PROK) is 362.44% up. Looking at the short shares, we see there were 16.8 million shares sold at short interest cover period of 32.47 days.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 35.6% from its current market value. According to analyst projections, PROK’s forecast low is 3 with 6 as the target high. To hit the forecast high, the stock’s price needs a -86.34% plunge from its current level, while the stock would need to tank 6.83% for it to hit the projected low.
ProKidney Corp (PROK) estimates and forecasts
Year-over-year growth is forecast to reach 126.97% up from the last financial year.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
The 2025 estimates are for ProKidney Corp earnings to increase by 10.31%, but the outlook for the next 5-year period is at -4.46% per year.
ProKidney Corp (NASDAQ:PROK)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 30.05% of ProKidney Corp shares while 41.66% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 59.55%. There are 41.66% institutions holding the ProKidney Corp stock share, with MORGAN STANLEY the top institutional holder. As of 2024-06-30, the company held 19.034% of the shares, roughly 14.45 million PROK shares worth $35.54 million.
SUVRETTA CAPITAL MANAGEMENT, LLC holds the second largest percentage of outstanding shares, with 12.306% or 9.34 million shares worth $22.98 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. With 2.97 shares estimated at $9.56 million under it, the former controlled 2.29% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 1.99% of the shares, roughly 2.58 shares worth around $8.3 million.
